Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.

Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR.

J Med Chem. 2018 Feb 8;61(3):934-945. doi: 10.1021/acs.jmedchem.7b01411. Epub 2018 Jan 5.

PMID:
29236497
2.

Data Standardization for Results Management.

Campbell RM, Dymshitz J, Eastwood BJ, Emkey R, Greenen DP, Heerding JM, Johnson D, Large TH, Littlejohn T, Montrose C, Nutter SE, Sawyer BD, Sigmund SK, Smith M, Weidner JR, Zink RW.

In: Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2017 Oct 20].

3.

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).

Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A.

J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11.

PMID:
27749056
4.

Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.

Hughes NE, Bleisch TJ, Jones SA, Richardson TI, Doti RA, Wang Y, Stout SL, Durst GL, Chambers MG, Oskins JL, Lin C, Adams LA, Page TJ, Barr RJ, Zink RW, Osborne H, Montrose-Rafizadeh C, Norman BH.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3274-3277. doi: 10.1016/j.bmcl.2016.05.056. Epub 2016 May 20.

PMID:
27261179
5.

Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists.

Burkholder TP, Cunningham BE, Clayton JR, Lander PA, Brown ML, Doti RA, Durst GL, Montrose-Rafizadeh C, King C, Osborne HE, Amos RM, Zink RW, Stramm LE, Burris TP, Cardona G, Konkol DL, Reidy C, Christe ME, Genin MJ.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1377-80. doi: 10.1016/j.bmcl.2015.02.062. Epub 2015 Mar 3.

PMID:
25752984
6.

Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.

Richardson TI, Clarke CA, Yu KL, Yee YK, Bleisch TJ, Lopez JE, Jones SA, Hughes NE, Muehl BS, Lugar CW, Moore TL, Shetler PK, Zink RW, Osborne JJ, Montrose-Rafizadeh C, Patel N, Geiser AG, Galvin RJ, Dodge JA.

ACS Med Chem Lett. 2010 Dec 9;2(2):148-53. doi: 10.1021/ml100220b. eCollection 2011 Feb 10.

7.

Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.

Shi Q, Canada EJ, Xu Y, Warshawsky AM, Etgen GJ, Broderick CL, Clutinger CK, Irwin LA, Laurila ME, Montrose-Rafizadeh C, Oldham BA, Wang M, Winneroski LL, Xie C, York JS, Yumibe NP, Zink RW, Mantlo N.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6744-9. Epub 2007 Oct 18.

PMID:
18029178
8.

Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.

Warshawsky AM, Alt CA, Brozinick JT, Harkness AR, Hawkins ED, Henry JR, Matthews DP, Miller AR, Misener EA, Montrose-Rafizadeh C, Rhodes GA, Shen Q, Vance JA, Udodong UE, Wang M, Zhang TY, Zink RW.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6328-33. Epub 2006 Sep 26.

PMID:
17005394
9.

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6293-7. Epub 2006 Sep 26.

PMID:
17005393
10.

The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand.

Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, Cheng CC, Zink RW, Barr RJ, Hepler CD, Krishnan V, Bullock HA, Burris LL, Galvin RJ, Bramlett K, Stayrook KR.

Mol Pharmacol. 2005 Mar;67(3):948-54. Epub 2004 Dec 15.

PMID:
15602004
11.

Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.

Wang M, Winneroski LL, Ardecky RJ, Babine RE, Brooks DA, Etgen GJ, Hutchison DR, Kauffman RF, Kunkel A, Mais DE, Montrose-Rafizadeh C, Ogilvie KM, Oldham BA, Peters MK, Rito CJ, Rungta DK, Tripp AE, Wilson SB, Xu Y, Zink RW, McCarthy JR.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6113-6.

PMID:
15546740
12.

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.

Xu Y, Mayhugh D, Saeed A, Wang X, Thompson RC, Dominianni SJ, Kauffman RF, Singh J, Bean JS, Bensch WR, Barr RJ, Osborne J, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Huang N, Luffer-Atlas D, Rungta D, Maise DE, Mantlo NB.

J Med Chem. 2003 Nov 20;46(24):5121-4.

PMID:
14613314
13.
14.

The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol.

June HL, McCane SR, Zink RW, Portoghese PS, Li TK, Froehlich JC.

Psychopharmacology (Berl). 1999 Nov;147(1):81-9.

PMID:
10591872
15.

Contribution of the opioid system to alcohol aversion and alcohol drinking behavior.

Froehlich JC, Badia-Elder NE, Zink RW, McCullough DE, Portoghese PS.

J Pharmacol Exp Ther. 1998 Oct;287(1):284-92.

PMID:
9765348

Supplemental Content

Support Center